Purple Biotech Ltd (TLV:PPBT)
Israel · Delayed Price · Currency is ILS · Price in ILA 1.000
0.00 (0.00%)
Sep 10, 2026, 1:51 PM IDT
Purple Biotech Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
10
Market Cap
18.65M ILS
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Evogene | 4.94M |
| BioLineRx | 4.15M |
| Can-Fite BioPharma | 1.21M |
| BioLight Life Sciences | 21.00K |
| Clal Biotechnology Industries | -118.00K |
Purple Biotech News
- 11 days ago - Why Is Purple Biotech (PPBT) Stock 42% Up Today? - TipRanks
- 11 days ago - Purple Biotech issued notice of allowance from USPTO - TheFly
- 11 days ago - New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies - GlobeNewsWire
- 5 weeks ago - Purple Biotech price target lowered to $17 from $30 at H.C. Wainwright - TheFly
- 3 months ago - Purple Biotech presents new IM1240 data at EACR - TheFly
- 3 months ago - Purple Biotech files $200M mixed securities shelf - TheFly
- 4 months ago - Purple Biotech reports IM1240 demonstrates potent anti-tumor activity - TheFly
- 5 months ago - Purple Biotech announces collaboration with Converge Bio - TheFly